ProQR Therapeutics N.V. (NASDAQ:PRQR) Sees Large Decrease in Short Interest

ProQR Therapeutics N.V. (NASDAQ:PRQR) saw a significant drop in short interest in April. As of April 15th, there was short interest totaling 1,261,281 shares, a drop of 24.4% from the March 31st total of 1,667,465 shares. Based on an average trading volume of 736,794 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.3% of the company’s stock are sold short.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. boosted its position in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the period. Guggenheim Capital LLC bought a new stake in ProQR Therapeutics during the 4th quarter valued at $35,000. Moody Lynn & Lieberson LLC acquired a new position in ProQR Therapeutics during the 4th quarter worth $50,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter worth $51,000. Finally, Fifth Third Bancorp bought a new position in shares of ProQR Therapeutics in the third quarter worth $64,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of ProQR Therapeutics stock traded down $0.02 on Friday, reaching $1.55. 462,829 shares of the company were exchanged, compared to its average volume of 525,223. ProQR Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.10. The firm has a market cap of $163.31 million, a price-to-earnings ratio of -3.37 and a beta of 0.10. The company’s 50-day moving average is $1.68 and its two-hundred day moving average is $1.94.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $6.12 million. As a group, sell-side analysts forecast that ProQR Therapeutics will post -0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, April 9th. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday, March 13th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $7.25.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.